Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Ray

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Bioanalysis|November 24, 2012
Tissue bioanalysis of biotherapeutics and drug targets to support PK/PDHendrik Neubert, Scott Fountain, Lindsay King, et al.
Pharmaceutical Research|January 7, 2006
Fit-for-purpose method development and validation for successful biomarker measurementJean W Lee, Viswanath Devanarayan, Yu Chen Barrett, et al.
Molecular Cancer Therapeutics|September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade TherapyBruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Bioanalysis|October 11, 2013
2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMSLauren Stevenson, Fabio Garofolo, Binodh DeSilva, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Bioanalysis|November 24, 2012
Tissue bioanalysis of biotherapeutics and drug targets to support PK/PDHendrik Neubert, Scott Fountain, Lindsay King, et al.
Pharmaceutical Research|January 7, 2006
Fit-for-purpose method development and validation for successful biomarker measurementJean W Lee, Viswanath Devanarayan, Yu Chen Barrett, et al.
Molecular Cancer Therapeutics|September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade TherapyBruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Bioanalysis|October 11, 2013
2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMSLauren Stevenson, Fabio Garofolo, Binodh DeSilva, et al.
Pageof 3